Last Updated : January 29, 2025
Details
FilesGeneric Name:
everolimus
Project Status:
Complete
Therapeutic Area:
Tuberous Sclerosis Complex (TSC)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0836-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
| Call for patient/clinician input open | 14-Dec-23 |
|---|---|
| Call for patient input open | 14-Dec-23 |
| Call for patient input closed | 12-Feb-24 |
| Call for patient/clinician input closed | 12-Feb-24 |
| Call for industry input open | 14-Dec-23 |
| Call for industry input closed | 12-Feb-24 |
| Submission received | 12-Dec-23 |
| Review initiated | 13-Dec-23 |
| Expert committee meeting (initial) | 19-Sep-24 |
| Draft recommendation posted for stakeholder feedback | 17-Oct-24 |
| End of feedback period | 31-Oct-24 |
| Final recommendation posted | 03-Dec-24 |
| CADTH review report(s) posted | 07-Nov-24 |
Files
Last Updated : January 29, 2025